<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151217">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733589</url>
  </required_header>
  <id_info>
    <org_study_id>[2012]-10-24</org_study_id>
    <nct_id>NCT01733589</nct_id>
  </id_info>
  <brief_title>Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC</brief_title>
  <official_title>Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Lianyungang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the
      local control of tumors, especially the squamous cell carcinomas. Preclinical models have
      shown that Endostar may transiently &quot;normalize&quot; the tumor vasculature to make it more
      efficient for oxygen delivery, thereby providing a window of opportunity for enhanced
      sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and
      efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT
      regimen in patients with unresectable stage III NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>from beginning treatment to progressive disease or the last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>complete response(CR); partial response(PR); stable disease(SD); progressive disease(PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>from date of beginning treatment until date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicities</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>radiation-induced esophagitis; radiation-induced pneumonia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Stage III Non-small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein  through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human endostatin</intervention_name>
    <description>Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.</description>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  untreated histologic or cytologic of NSCLC verified

          -  inoperable stage IIIA or IIIB NSCLC

          -  measurable disease by RECIST

          -  18~70 years of age

          -  an ECOG PS of 0 to 1

          -  absolute neutrophil count (ANC) of ≥1500/μL, hemoglobin ≥10gm/dL, platelet
             ≥100,000/μL

          -  serum creatinine ≤1.25 times of upper limit of normal (ULN), calculated creatinine
             clearance (CrCl) of ≥60ml/min

          -  bilirubin 1.5×ULN, AST and ALT less than 2.5×ULN, alkaline phosphatase less than
             5×ULN

          -  forced vital capacity in 1 second (FEV1) higher than 0.8 L

          -  CB6 is normal

          -  Written informed consent

        Exclusion Criteria:

          -  a history of other malignant diseases

          -  any contraindications for chemoradiotherapy

          -  distant metastasis

          -  malignant pleural and/or pericardial effusion

          -  pregnant or nursing

          -  preexisting bleeding diatheses or coagulopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Chen, M.D.</last_name>
    <phone>+86 18758875572</phone>
    <email>gzcm@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen, M.D.</last_name>
      <phone>0086-571-88122068</phone>
      <email>gzcm@263.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 23, 2012</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human endostatin</keyword>
  <keyword>Non-small-Cell Lung Cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
